It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Long-term, uncontrolled diabetes mellitus can lead to micro- and macrovascular problems. The protective function of lncRNA LYPLAL1 is to reduce endothelium cell inflammation by upregulating sirtuin 1 (SIRT1) and reducing microRNA (miR)-204-5p. This work attempted to examine the lncRNA LYPLAL1/miR-204-5p/SIRT1 molecules as diagnostic biomarkers for diabetic MVC and to assess their clinical correlations. The study enrolled 32 controls, 32 patients with diabetes alone, and 32 patients with diabetic MVC. RT-qPCR, or quantitative real-time PCR, was utilized to determine the expression levels of lncRNA and miR. SIRT1 was measured by ELISA. When comparing cases with MVC to those without MVC, the lncRNA LYPLAL1 and SIRT1 values were significantly lower. Conversely, patients with MVC had significantly higher miR-204-5p levels than those without MVC. The LncRNA LYPLAL1 performed best in terms of detecting MVC. It attained 90.6% specificity and 96.9% sensitivity. A combination of three markers (lncRNA LYPLAL1, miR-204-5p, and SIRT1) yielded the best accuracy at 98.4%. LYPLAL1 expression appeared to be an independent MVC predictor. Adjusted OR for LYPLAL1 expression was 405 (95% CI: 1.4–1200) (p = 0.039). When we compared cases with MVC to those without MVC, the lncRNA LYPLAL1 and SIRT1 values were significantly lower. Patients with MVC had significantly higher miR-204-5p levels than those without MVC. LYPLAL1 LncRNA demonstrated the best performance characteristics. LncRNA LYPLAL1 expression is an independent predictor of MVC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Jouf University, Department of Pathology, Biochemistry Division, College of Medicine, Sakaka, Saudi Arabia (GRID:grid.440748.b) (ISNI:0000 0004 1756 6705)
2 Zagazig University, Clinical Pathology Department, Faculty of Human Medicine, Zagazig, Egypt (GRID:grid.31451.32) (ISNI:0000 0001 2158 2757)
3 Jouf University, Biology Department, College of Science, Sakakah, Saudi Arabia (GRID:grid.440748.b) (ISNI:0000 0004 1756 6705)
4 University of Jeddah, Department of biological science, College of Science, Jeddah, Saudi Arabia (GRID:grid.460099.2) (ISNI:0000 0004 4912 2893)
5 Zagazig University, Internal Medicine Department, Faculty of Human Medicine, Zagazig, Egypt (GRID:grid.31451.32) (ISNI:0000 0001 2158 2757)
6 Zagazig University, Microbiology and Immunology Department, Faculty of Human Medicine, Zagazig, Egypt (GRID:grid.31451.32) (ISNI:0000 0001 2158 2757)
7 Zagazig University, Cardiology Department, Faculty of Human Medicine, Zagazig, Egypt (GRID:grid.31451.32) (ISNI:0000 0001 2158 2757)